Evidence map›Paper›PMID 38455773›Full record

ReviewCureus2024

Precision Population Cancer Medicine in Cancer of the Uterine Cervix: A Potential Roadmap to Eradicate Cervical Cancer.

Mary R Nittala, Johnny Yang, Alexander E Velazquez, John D Salvemini, Gregory R Vance, Camille C Grady, Bradley Hathaway, Jeffrey A Roux, Srinivasan Vijayakumar

Abstract readReview
In one paragraph

Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mary R NittalaRadiation Oncology, University of Mississippi Medical Center, Jackson, USA.
Johnny YangRadiation Oncology, University of Mississippi Medical Center, Jackson, USA.
Alexander E VelazquezRadiation Oncology, University of Mississippi Medical Center, Jackson, USA.
John D SalveminiRadiation Oncology, University of Mississippi Medical Center, Jackson, USA.
Gregory R VanceRadiation Oncology, University of Mississippi Medical Center, Jackson, USA.
Camille C GradyRadiation Oncology, University of Mississippi Medical Center, Jackson, USA.
Bradley HathawayRadiation Oncology, University of Mississippi Medical Center, Jackson, USA.
Jeffrey A RouxRadiation Oncology, University of Mississippi Medical Center, Jackson, USA.
Srinivasan VijayakumarRadiation Oncology, University of Mississippi Medical Center, Jackson, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the success of the Human Genome Project, the era of genomic medicine (GM) was born. Later on, as GM made progress, there was a feeling of exhilaration that GM could help resolve many disease processes. It also led to the conviction that personalized medicine was possible, and a relatively synonymous word, precision medicine (PM), was coined. However, the influence of environmental factors and social determinants of diseases was only partially given their due importance in the definition of PM, although more recently, this has been recognized. With the rapid advances in GM, big data, data mining, wearable devices for health monitoring, telemedicine, etc., PM can be more easily extended to population-level health care in disease management, prevention, early screening, and so on.and the term precision population medicine (PPM) more aptly describes it. PPM's potential in cancer care was posited earlier,and the current authors planned a series of cancer disease-specific follow-up articles. These papers are mainly aimed at helping emerging students in health sciences (medicine, pharmacy, nursing, dentistry, public health, population health), healthcare management (health-focused business administration, nonprofit administration, public institutional administration, etc.), and policy-making (e.g., political science), although not exclusively. This first disease-specific report focuses on the cancer of the uterine cervix (CC). It describes how recent breakthroughs can be leveraged as force multipliers to improve outcomes in CC - by improving early detection, better screening for CC, potential GM-based interventions during the stage of persistent Human papillomavirus (HPV) infection and treatment interventions - especially among the disadvantaged and resource-scarce populations. This work is a tiny step in our attempts to improve outcomes in CC and ultimately eradicate CC from the face of the earth.

Indexed as

big-datacancer preventiongenomic medicineprecision medicineprecision population medicineuterine cervical cancer

Identifiers

PMID38455773
PMCPMC10919943

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.